Clinical Study

A041703- A Phase II Study Of Inotuzumab Ozogamicin Followed By Blinatumomab For Ph-Negative Cd22-Positive B-Lineage Acute Lymphoblastic Leukemia In Newly Diagnosed Older Adults Or Adults With Relapsed Or Refractory Diseas

Posted Date: Nov 28, 2020

  • Investigator: Emily Curran
  • Specialties: Cancer, Leukemia, Oncology
  • Type of Study: Drug

This phase II trial studies how well inotuzumab ozogamicin and blinatumomab work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back, or does not respond to treatment. The primary goal of this study is to determine Event Free survival.


To Be Eligible: Must Have Morphologic Diagnosis Of Cd22-Positive Precursor B-Cell Acute Lymphoblastic Leukemia (All), Adequate Organ Function, Ecog 0-2, No Unstable Cardiac Disease Or Impaired Cardiac Function, No Additional Malignancy Within 2 Years, No Prior Treatment With Inotuzumab Ozogamicin, Blinatumomab, Other Cd22-Directed Therapy, Or Other Cd19-Directed Therapy


All, Leukemia

For More Information:

Uc Cancer Center